Q3 2025 Management View CEO Rainer Blair emphasized strong third quarter results, driven by "DBS-driven execution paired with ...

SUNNYVALE, Calif., Sept. 29, 2020 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress ...

Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

These include fast, accurate, and easy to use tests for SARS-CoV-2, the virus causing COVID-19, Flu, MRSA, tuberculosis, and other HAI, sexual health, and oncology diseases. Each test is designed for ...

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in ...

Danaher will purchase Cepheid, a medical diagnostics company located in Sunnyvale, Calif., for a value of $4 billion, according to Reuters. Danaher develops technology for the dental, life sciences, ...

(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...

NEW YORK (CBS.MW) -- Shares of Cepheid surged out ahead of other biotechnology stocks Monday after the company said it was developing new systems that could be used in detecting biological weapons.